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Introduction: Arthritis is the most frequent manifestation of Blau syndrome, an autoinflammatory disorder caused
by the genetic mutation of NOD2. However, detailed information on arthritis in Blau syndrome on which the
therapeutic strategy should be based on is lacking. This multi-center study aimed to accurately characterize the
articular manifestation of Blau syndrome and also to demonstrate the utility of musculoskeletal ultrasound in Blau
syndrome.
Methods: Patients who had been diagnosed with Blau syndrome by genetic analysis of NOD2 were recruited. A
total of 102 synovial sites in 40 joints were assessed semiquantitatively by ultrasound for gray-scale synovitis and
synovial power Doppler (PD) signal.
Results: In total, 10 patients whose age ranged from 10 months to 37 years enrolled in this study. Although only 4
joints (0.8%) were tender on physical examination, 81 joints (16.9%) were clinically swollen. Moreover, 240 (50.0%), and
124 (25.8%) joints showed gray-scale (GS) synovitis and synovial PD signal on ultrasound, respectively. Importantly, GS
synovitis was present in 168 out of 399 non-swollen joints, in which 61 also exhibited synovial PD signal. Among 40
joint regions, the ankle, the wrist, and the proximal interphalangeal joints were the most frequently and severely
affected joints. Comparisons between different synovial tissues demonstrated a significantly higher proportion of the
joints with tenosynovitis as compared with that with intra-articular synovitis (41.5% versus 27.9%, P < 0.0001). In respect
of age and treatment, synovial PD signals were minimal in the youngest patient and in the oldest two patients, and
were relatively mild in patients receiving treatment with methotrexate plus TNF antagonists. In two patients who
underwent the second ultrasound examination, total PD scores markedly decreased after initiating the treatment with
a tumor necrosis factor (TNF) antagonist.
Conclusions: The detailed information on synovial inflammation obtained by ultrasound confirms the dissociation
between pain and inflammation and the frequently involved joint regions and synovial tissue in the arthritis of Blau
syndrome. Our data also demonstrate that ultrasonography can be a potent tool in monitoring the activity of synovial
inflammation and in investigating the pathophysiology of arthritis in this rare but archetypical autoinflammatory
condition.* Correspondence: K.Ikeda@faculty.chiba-u.jp
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Blau syndrome (MIM #186580) is a rare autoinflamma-
tory disorder, which was first described in 1985 by the
pediatrician Edward Blau as a dominantly inherited,
chronic inflammatory syndrome characterized by the clin-
ical triad of granulomatous dermatitis, symmetric arthritis
and recurrent uveitis [1]. In 2001, Miceli-Richard et al.
identified the gene that confers susceptibility for Blau syn-
drome, discovering three mis-sense mutations (R334Q,
R334W and L469F) in the region encoding the nucleo-
tide-binding oligomerization domain (NOD) of the cas-
pase recruitment domain gene (CARD15/NOD2) in four
French and German affected families [2]. In spite of the
striking clinical similarities with Blau syndrome, early
onset sarcoidosis (EOS, MIM #609464) was originally
considered a distinct disease entity. However, subsequent
genetic analyses have shown that many patients with EOS
have mutations in NOD2 [3-6] and these two diseases and
other variant forms are now considered to represent a
pathophysiologically identical condition in which in-
creased NFκB activity driven by mutated NOD2 gene plays
a significant role [3,6-11].
Arthritis is the most frequent manifestation of Blau syn-
drome and usually becomes clinically apparent within the
first decade of life [1,5,7,11-15]. Joint manifestation in Blau
syndrome has been reported to be chronic, symmetrical,
and mostly painless polyarthritis. Marked soft-tissue swell-
ing can occur due to granulomatous inflammation in both
intra-articular synovium and tenosynovium, which can
cause characteristic camptodactyly (that is, flexion con-
tracture of fingers and toes) and, occasionally, subsequent
impairment of physical function. However, the precise
location and severity of joint inflammation in patients
with Blau syndrome have not been systematically eva-
luated because of the difficulty to accurately determine
with physical examination the activity of current inflam-
mation in mostly non-tender joints in children.
Musculoskeletal ultrasound is a relatively inexpensive
imaging modality, which enables more accurate assess-
ment of synovial inflammation than physical exami-
nation does [16-19] and, therefore, provides improved
accuracy in the diagnosis [20-24] and the disease activity
monitoring [19,23-29] of rheumatoid arthritis (RA). As
ultrasound is a non-invasive technique, which patients
can undergo with minimal restriction, its use in pediatric
inflammatory conditions such as juvenile idiopathic
arthritis (JIA) has been increasingly studied [30-33]. We
recently reported representative ultrasound images that
clearly visualized the tenosynovitis in a patient with Blau
syndrome [34]; however, no other papers have reported
the use of ultrasound in the assessment of synovial in-
flammation in Blau syndrome.
In this pilot, multicenter study, 10 patients with Blau
syndrome whose NOD2 mutation had been confirmedunderwent comprehensive ultrasound examination of
102 synovial sites, aiming to accurately characterize the
articular manifestation of Blau syndrome and also to
demonstrate the utility of musculoskeletal ultrasound in
Blau syndrome.
Patients and methods
Patients and NOD2 mutation analysis
In this cross-sectional study, patients who had been diag-
nosed with Blau syndrome by genetic analysis of NOD2
were recruited. Age- and sex-matched control subjects
who did not have arthritic symptoms were also recruited.
Written informed consent was obtained from the patient/
subject, or his/her family member if necessary, according
to the study protocol approved by the Ethics Committee
of Chiba University, Kyoto University, and Kagoshima
University in accordance with the Declaration of Helsinki.
Genomic DNA was extracted from the peripheral blood
of the patients, and sequencing of all exons and exon-
intron junctions of NOD2 was performed as previously
described [6].
Clinical and laboratory assessment
Clinical information collected was complete medical his-
tory including current and previous medication for Blau
syndrome, tender and swollen joint counts in 40 joints
(disease activity score in 28 joints (DAS28) + bilateral
ankle and metatarsophalangeal (MTP) joints), patient’s/
parent’s and physician’s global visual analogue scale (VAS),
erythrocyte sedimentation rate (ESR), serum levels of
C-reactive protein (CRP) and matrix metalloproteinase-3
(MMP-3), childhood health assessment questionnaire-
disability index (CHAQ-DI), and the presence of campto-
dactyly in fingers and toes.
Ultrasound examination
A systematic multiplanar gray-scale (GS) and power Dop-
pler (PD) ultrasound was performed in a temperature-
controlled room on the same day of the clinical evaluation
by a rheumatologist who was experienced in musculoske-
letal ultrasound (KI) using an HI VISION Ascendus with
a linear array multi-frequency transducer (5 to 18 MHz
for GS, 7.5 MHz for PD) (Hitachi Medical Corporation,
Tokyo, Japan). PD ultrasound was performed with a pulse
repetition frequency set at 800 Hz and a low wall filter.
Color gain was set just below the level at which color
noise appeared.
Ultrasound was performed on the 40 joints which
were clinically assessed for joint counts. Middle and
large joints were divided into individual joints which
compose the larger joint unit (for example, humeroradial
and humeroulnar joints in the elbow) or into multiple
parts of the joint (for example, suprapatellar recess,
medial and lateral aspects of femorotibial joints in the
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separately evaluated (Figure 1). In addition to the intra-
articular synovium, we also evaluated the major peri-
articular synovial tissues; a total of 44 tenosynovial sites
(Figure 2) and 4 bursal sites (bilateral sub-acromial/del-
toid bursae) were examined. All sites were scanned tho-
roughly in multiple imaging planes so that the whole
lesion was evaluated. As no ultrasound definitions of
synovial pathology have been established for children,
we based our assessment on the ultrasound definitionsGS/
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Figure 2 Ultrasound scores for tenosynovitis in patients with Blau syndrome. Semiquantitative grades (0 to 3) for gray-scale synovitis and
synovial power Doppler signal in individual joint regions are shown with heat maps. Total sum of the scores in each case is shown in the rightmost
column. *First ultrasound examination (before treatment); **second ultrasound examination (after treatment). GS, gray-scale; PD, power Doppler; No,
case number; R, right; L, left; FT, flexor tendon; Comp, compartment; ETs, extensor tendons (flexor digitorum superficialis/profundus and flexor carpi
radialis); LHB, long head of biceps tendon; EDL, extensor digitorum longus; EHL, extensor hallucis longus; TA, tibialis anterior; TP, tibialis posterior; FDL,
flexor digitorum longus; PL, peroneus longus; PB, peroneus brevis.
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sion of how large the volume of synovial hypertrophy and
synovial fluid was for the synovial site assessed. On the
other hand, synovial PD signal was graded as a PD score
on a scale of 0 to 3 (grade 0, normal; grade 1, mild; grade
2, moderate; grade 3, severe) based on the rater’s impres-
sion of how widespread the abnormal synovial PD signals
within the synovial hypertrophy were. Total scores for anindividual patient were calculated for each synovial tissue
and for all synovial tissues by summation for each synovial
tissue (that is, total intra-articular GS/PD score, total teno-
synovial GS/PD score, total bursal GS/PD score) and for
all synovial tissues (that is, total synovial GS/PD score).
When ultrasound findings were assessed at a 40-joint
level, the maximum grade obtained from multiple synovial
sites (for example, radiocarpal joint, extensor carpi
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example, wrist).Statistical analysis
Statistical analysis was performed using R version 2.13.0
(The R Foundation for Statistical Computing, Vienna,
Austria). Non-normally distributed continuous data were
analyzed using nonparametric tests (Spearman’s rank
correlation coefficient and Wilcoxon signed-rank test).
Categorical data were analyzed using McNemar’s test.
Bonferroni’s correction was applied for multiple testing.
P-values less than 0.05 were considered statistically
significant.Results
Demographics and disease characteristics
Ten patients (two female) from eight unrelated Japanese
families enrolled in this study. As shown in Table 1, the age
at ultrasound examination ranged from 10 months to
37 years and the patients were numbered from 1 to 10 in
order of this age. Patients 1, 2, and 10 were offspring and a
parent, whereas the other patients had no family history
suggestive of Blau syndrome. All patients had been shown
to have a known NOD2 gene mutation associated with Blau
syndrome (Table 1). Patient 3 was an atypical case who de-
veloped aortitis at the age of 7 months, which was treated
successfully with corticosteroid (pulse methylprednisolone
followed by oral prednisolone for 5 years), methotrexate,
and infliximab as infantile Takayasu arteritis. He was
genotyped for NOD2 when he developed iritis at the age














1† R334W 10 NA 6 NA
2† ref [34] R334W 66 19 6 NA
3 ref [36] D382E 111 NA NA 88
4 R587C 115 53 NA NA
5 R334W 146* 24 7 39
154**
6 R334W 153* 29 21 35
166**
7 ref [6] R334Q 160 52 NA NA
8 ref [6] R334W 212 24 8 48
9 ref [6] R334Q 294 34 24 60
10† ref [3] R334W 452 NR‡ 24 156
ref: Reference number in which the patient was previously reported; †offspring and paren
symptoms despite the presence of overt camptodactyly. NSAID, non-steroidal anti-inflamTreatment at ultrasound examination
Three patients (patients 1, 5, and 10) were not receiving
any medication for joint involvement when ultrasound
was performed, and seven patients were receiving anti-
inflammatory/rheumatic medications, including non-
steroidal anti-inflammatory drugs (NSAIDs), corticos-
teroids (prednisolone ≤11.25 mg/day), methotrexate, and
TNF antagonists (Table 1). In patient 5, treatment with
methotrexate plus infliximab was initiated after the first
ultrasound examination and the second ultrasound
examination was performed after 14 weeks of treat-
ment. In patient 6, infliximab was added to his treat-
ment regimen after the first ultrasound examination
and the second ultrasound examination was performed
after 12 months.
Severity of arthritis assessed by conventional measures
Table 2 summarizes the severity of arthritis at ultrasound
examination. Although swollen joint counts varied among
patients, most of the patients did not have any tender
joints and therefore, the patient’s or parent’s global VAS
score was ≤10 mm in most of the patients. The levels of
acute inflammatory responses and physician’s global VAS
score were not markedly elevated either. As shown in
Table 2, disease activity parameters in patient 5 substan-
tially improved after treatment with methotrexate plus
infliximab, whereas the decrease in those parameters in
patient 6 was relatively mild.
Camptodactyly was present at least in one joint in pa-
tients 4 to 10, whose ages were 9 years and 7 months or
older (Table 2). Proximal interphalangeal (PIP) joints
were the joints in which camptodactyly was identified
most frequently. Despite the presence of multipleat ultrasound examination
Duration of treatment at ultrasound examination (months)
iagnosis
veitis
NSAID Corticosteroid Methotrexate TNF antagonist
NA NA NA NA
NA NA 13 NA
NA NA 60 11 (infliximab)
NA NA 32 32 (etanercept)
NA NA NA NA
NA NA 3 3 (infliximab)
12 112 124 NA
NA NA 137 12 (infliximab)
105 NA 60 44 (infliximab)
188 142 184 NA
270 259 135 45 (infliximab)
NA NA NA NA
t; *1st ultrasound examination; **2nd ultrasound examination; ‡reported no arthritic
matory drug; TNF, tumor necrosis factor; NR, not reported; NA, not applicable.



















/28 /40 /28 /40 Patient/parent Physician ESR, mm/h CRP, mg/L
1 NR† NR† 0 0 0 2 3 (2 to 10) 3.0 (0 to 3) NA NA 27.2 0 No
2 0 0 22 24 10 5 6 (2 to 10) 1.0 (0 to 3) 2.7 2.7 85.3 0 No
3 0 0 0 0 0 3 29 (2 to 10) 32.0 (0 to 3) 2.4 2.2 24.9 0 No
4 0 0 1 1 8 6 19 (3 to 15) 0.7 (0 to 2.6) 2.5 1.5 64.0 0.13 Yes
5* 0 0 23 25 10 50 22 (1 to 10) 6.0 (0 to 3) 3.7 3.1 800.0 0 Yes
5** 0 0 7 9 0 23 3 (1 to 10) 0.0 (0 to 3) 1.5 1.7 21.8 0 Yes
6* 0 0 2 3 1 5 3 (5 to 13) 3.0 (0 to 2) 1.3 1.9 18.7 0 Yes
6** 0 0 2 2 2 1 2 (5 to 13) 0.4 (0 to 2) 0.9 1.5 18.8 0 Yes
7 0 0 1 1 0 0 27 (3 to 15) 1.4 (0 to 2.6) 2.6 1.6 426.4 0 Yes
8 4 4 13 13 65 45 8 (2 to 10) 1.0 (0 to 2.6) 4.5 4.3 36.9 0.63 Yes
9 0 0 0 0 15 8 4 (2 to 10) 0.0 (0 to 2.6) 1.2 1.2 216.8 1.63‡ Yes
10 0 0 3 5 4 8 12 (2 to 10) 1.0 (0 to 3) 2.3 1.8 129.0 0.13‡ Yes
*1st ultrasound examination ; **2nd ultrasound examination; †not reported because the patient was not able to understand and answer the question; ‡health
assessment questionnaire-damage index (HAQ-DI) for adult was obtained; §normal range in the institute for patient’s sex is provided; §§normal ranges are 36.9 to
121.0 ng/mL for males and 17.3 to 59.7 ng/mL for females. VAS, visual analogue scale; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, disease
activity score 28; MMP-3, matrix metalloproteinase-3; CHAQ, childhood-health assessment questionnaire; NR, not reported; NA, not applicable.
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assessed by CHAQ/HAQ was rarely impaired in patients
younger than 13 years. Photographs of the hands and
the right foot and radiographs of the hands in patient 5
are shown in Figures 3 and 4, respectively.Figure 3 Photographs of the hands and the right foot in patient 5. Sh
(B, D) in Patient 5 before treatment (A, B) and after treatment (C, D). Soft
improved after treatment with methotrexate and infliximab. Papular rash aDistribution of inflammation in synovial tissues
determined by ultrasound
All patients completed the comprehensive ultrasound as-
sessment of 102 synovial sites. The distribution and the
grade of GS and PD scores in each patient were illustratedown are the photographs of the hands (A, C) and the right foot
tissue swelling in the wrists, the fingers, the ankle, and the mid foot
lso markedly improved.
Figure 4 Radiographs of the hands in patient 5. Shown are the radiographs of the left hand (A, C) and the right hand (B, D) in patient 5
before treatment (A, B) and after treatment (C, D). Soft tissue swelling in the wrist and fingers improved after treatment with methotrexate
and infliximab.
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http://arthritis-research.com/content/16/2/R89in heat maps for intra-articular synovitis (Figure 1) and for
tenosynovitis (Figure 2). Bursitis was identified only in the
sub-acromial/deltoid bursa in bilateral shoulders in one
patient (patient 6) with a GS score of 2 bilaterally and a
PD score of 2 in the right shoulder (data not shown).
As demonstrated in Figures 1 and 2, a wide range of
synovial sites were affected, mostly in a symmetrical






























Figure 5 Representative ultrasound images of intra-articular synovitis
ultrasound images of intra-articular synovitis (A, C, E, G, I, K) and tenosyno
(G-L). All images before treatment demonstrate synovial/tenosynovial hype
Additional movie files show this in more detail (see Additional files 1, 2, 3,
proximal interphalangeal joint in the right hand; (B and H) longitudinal vie
oblique view of the anterior-lateral aspect of the suprapatellar recess in the
in the right ankle; (E and K) longitudinal view of the dorsal aspect of the t
view of the flexor tendon of the first toe of the right foot. *Intra-articular sy
MP, metacarpal; FD, flexor digitorum; TA, tibialis anterior; MT, metatarsal.are shown in Figure 5. Additional movie files show these
in more detail (see Additional files 1, 2, 3, 4, 5 and 6).
The most frequently and severely involved synovial sites
were tendon sheaths in the ankle, extensor tendon
sheaths in the wrist, and the PIP joints. In contrast,
some synovial sites, such as the glenohumeral joint, the
midtarsal joint, and the olecranon bursa, did not exhibit











and tenosynovitis in patient 5. Shown are the representative
vitis (B, D, F, H, J, L) in patient 5 before (A-F) and after treatment
rtrophy, which accompanies increased power Doppler signals (A-F).
4, 5 and 6). (A and G) Longitudinal view of the dorsal aspect of the 3rd
w of the flexor tendon of the third finger on the right hand; (C and I)
right knee; (D and J) a longitudinal view of the tibialis anterior tendon
hird metatarsophalangeal joint of the right foot; (F and L) longitudinal
novial hypertrophy; **tenosynovial hypertrophy. PP, proximal phalanx;
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mean age 169.8 months old (range 3 to 499) also under-
went comprehensive ultrasound assessment. Only mild
GS intra-articular synovitis and tenosynovitis without a
PD signal was identified in subjects aged 3 years or older.
GS intra-articular synovitis was identified in nine sites in
eight joints (three wrists, three toes) in four patients and
GS tenosynovitis was identified in five sites in four joints
(three ankles) in four patients. These data indicate that GS
scores of 2 or greater and positive PD scores have patho-
logical meanings, whereas GS scores of 1 are less specific
in our study.
Predominance of tenosynovitis over intra-articular
synovitis
Tenosynovitis was more prevalent and more severe than
intra-articular synovitis in our patients with Blau syn-
drome (Figures 1 and 2). When compared in the total
joints where both intra-articular- and teno-synovitis were
evaluated (that is, elbow and knee joints were excluded),
the proportion of the joints with a positive GS score
for tenosynovitis was significantly higher than that for
intra-articular synovitis (41.5% versus 27.9%, P <0.0001,
McNemar test with Bonferroni correction). When com-
pared in each joint, the prevalence of GS tenosynovitis
was significantly higher than that of GS intra-articular
synovitis in the metacarpophalangeal (MCP) joints (56.0%
versus 25.0%, P <0.0001), in the wrist (80.0% versus 30.0%,
P = 0.0266), and in the ankle (100% versus 20.0%,
P = 0.0011) (McNemar test with Bonferroni correction)
(Figure 6A). Similarly, the proportion of the joints with a
positive PD score for tenosynovitis was significantly higher
than that for intra-articular synovitis in the total joints
(22.2% versus 15.2%, P <0.0001), and individually, in
the wrist (55.0% versus 15.0%, P = 0.0460) and in the
ankle (60.0% versus 0.0%, P = 0.0090) (McNemar test with
Bonferroni correction) (Figure 6B). In addition, the GS
and PD scores for tenosynovitis were significantly higher
than those for intra-articular synovitis in the total joints
(P <0.0001 for both scores, Wilcoxon signed-rank test
with Bonferroni correction).
Improvement of ultrasound findings after initiating the
treatment with infliximab
In patient 5, clinical, radiographic, and ultrasonographic
findings markedly improved after 14 weeks of treatment
with methotrexate plus infliximab (total intra-articular
GS score, 89 versus 13; total intra-articular PD score, 80
versus 7; total tenosynovial GS score, 79 versus 19; total
tenosynovial PD score, 72 versus 8) (Figures 1, 2, 3, 4
and 5). This result suggests that treatment with metho-
trexate plus infliximab can improve the inflammation in
synovial tissues in a patient with Blau syndrome in a
relatively short period of time.Adding infliximab to methotrexate also substantially im-
proved the ultrasound findings in patient 6, leaving no re-
sidual PD signals in the synovial tissues even after the
corticosteroid and the NSAID were discontinued (total
intra-articular GS score, 20 versus 10; total intra-articular
PD score, 7 versus 0; total tenosynovial GS score, 44 ver-
sus 6; total tenosynovial PD score, 24 versus 0) (Figures 1
and 2). These data indicate that ultrasound scores are
more responsive to change as compared with conven-
tional measures.
Influence of age and treatment on inflammation in
synovial tissues
Also demonstrated in Figures 1 and 2, together with
Table 1, is the influence of age and treatment on synovial
inflammation. Focusing on the PD score, severe cases
of intra-articular synovitis clustered between patient 5
(12 years and 2 months old) and patient 8 (18 years and
8 months old) (Figure 1). On the other hand, severe cases
of tenosynovitis clustered between patient 2 (5 years and
6 months old) and patient 8 (Figure 2). Of note, ultra-
sound revealed little or no inflammation accompanying
the PD signal in patient 1 (10 months old) and patient 10
(37 years and 8 months old) even though they had ne-
ver received anti-inflammatory or rheumatic treatment,
whereas patient 2, who is a member of the same family
carrying the same NOD2 mutation, exhibited substantial
PD tenosynovitis despite receiving an NSAID and metho-
trexate. Patients within the cluster whose ultrasound im-
ages showed relatively mild PD signals (patients 3, 4, 5
(after treatment) and 6 (after treatment)) were all recei-
ving treatment with methotrexate plus a TNF antagonist.
Discrepancy between ultrasound scores and conventional
measures for the activity of arthritis
As shown in Table 3, the swollen joint count tended to
correlate with total ultrasound scores (ρ 0.68 to 0.76,
P 0.0364 to 0.1343). However, no other conventional
measures for arthritis activity correlated with total ultra-
sound scores with statistical significance.
At a 40-joint level, numbers of joints with tenderness,
swelling, GS ≥1 synovitis (GS score ≥1), GS ≥2 synovitis
(GS score ≥2), and synovial PD signal were 4 (0.8%), 81
(16.9%), 240 (50.0%), 117 (24.4%), and 124 (25.8%), re-
spectively. The differences in prevalence between swel-
ling and ultrasound findings were statistically significant
(swelling versus GS ≥1 synovitis, P <0.0001; swelling ver-
sus GS ≥2 synovitis, P = 0.0002; swelling versus synovial
PD signal, P <0.0001) (McNemar test with Bonferroni
correction). Importantly, GS ≥1/GS ≥2 synovitis was
present in 168/57 out of 399 non-swollen joints, in
which 61 also exhibited synovial PD signal (Table 4).
In each joint region, prevalence of GS ≥1 synovitis
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Figure 6 Prevalence of intra-articular synovitis and tenosynovitis in each joint. Shown are the comparisons of prevalence of joints with a
positive gray-scale (A) or power Doppler (B) score between intra-articular synovitis (light gray/orange bar) and tenosynovitis (dark gray/orange
bar) in each joint. Numbers of total joints assessed for the region are shown in the bottom (n). *P <0.05, **P <0.01, ***P <0.001, McNemar test
with Bonferroni correction. GS, gray-scale; PD, power Doppler; PIP (IP), proximal interphalangeal (interphalangeal) joint; MCP, metacarpophalangeal
joint; MTP, metatarsophalangeal joint.
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http://arthritis-research.com/content/16/2/R89PIP joints (73.3% versus 24.2%, P <0.0001), the MCP joints
(55.0% versus 15.0%, P <0.0001), and the ankle (100% ver-
sus 37.6%, P = 0.0072) (McNemar test with Bonferroni
correction) (Figure 7). Prevalence of GS ≥1 synovitis and
synovial PD signal were also significantly higher than that
of joint swelling in the MCP joints (29.2% and 31.7%
versus 15.0%, P = 0.0058 and P = 0.0012, respectively,





Intra-articular synovium Total GS score 0.30 0.76*
Total PD score 0.35 0.69
Tenosynovium Total GS score 0.00 0.68
Total PD score 0.55 0.72
Total Total GS score 0.20 0.72
Total PD score 0.37 0.68
Values are Spearman’s correlation coefficients (ρ). *P < 0.05; no other correlations w
analogue scale; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28
PD, power Doppler.Discussion
In this multi-center study, ultrasonographic assessment of
102 synovial sites provided detailed information on the
anatomical distribution of synovial inflammation in pa-
tients with Blau syndrome. Our data demonstrate that a
wide range of synovial sites can be affected mostly in a
symmetrical manner in patients with Blau syndrome.





ESR CRP DAS28 -ESR DAS28 -CRP MMP-3
0.36 0.51 0.21 0.11 0.53 0.55 0.19
0.18 0.40 0.20 0.25 0.63 0.61 0.45
0.42 0.47 0.13 0.21 0.67 0.57 0.45
0.40 0.51 0.23 0.17 0.66 0.59 0.30
0.34 0.39 0.21 0.28 0.67 0.59 0.33
0.35 0.51 0.27 0.12 0.66 0.53 0.25
ere statistically significant when Bonferroni correction was applied. VAS, visual
, disease activity score 28; MMP-3, matrix metalloproteinase-3; GS, gray-scale;




Gray-scale synovitis (−) 231 (48) 9 (2) 240 (50)
(gray-scale score ≥1) (+) 168 (35) 72 (15) 240 (50)
Total 399 (83) 81 (17) 480 (100)
Gray-scale synovitis (−) 342 (71) 21 (4) 363 (75)
(gray-scale score ≥2) (+) 57 (12) 60 (13) 240 (25)
Total 399 (83) 81 (17) 480 (100)
Synovial (−) 338 (70) 18 (4) 356 (74)
Power Doppler signal (+) 61 (13) 63 (13) 124 (26)
Total 399 (83) 81 (17) 480 (100)
Values are the number (%) of joint regions.
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our data provide novel and more specific information on
the anatomical site (intra-articular synovium versus teno-
synovium versus bursa), the chronicity (currently active
inflammation versus chronic swelling versus subsequent
contracture), and the severity (mild versus severe). As a
result, the data in the form of a heat map (Figures 1 and
2) readily provide clinicians and researchers with valuable
information. Furthermore, our data for the first time de-
monstrate the predominance of tenosynovitis over intra-
articular synovitis in Blau syndrome. Although frequent
involvement of the tenosynovium has been reported de-
scriptively [1,7,13-15], no studies had provided objective




















Figure 7 Prevalence of clinical manifestations and ultrasound
findings in each joint. Shown are the proportions of joints with
tenderness (white bar), swelling (light blue bar), gray-scale synovitis≥
grade 1 (light gray bar), gray-scale synovitis≥ grade 2 (dark gray bar),
and synovial power Doppler signal (orange bar). Numbers of total
joints assessed for the region are shown in the bottom (n). **P <0.01,
***P <0.001, McNemar test with Bonferroni correction. GS, gray-scale
score; PD, power Doppler score; PIP (IP), proximal interphalangeal
(interphalangeal) joint; MCP, metacarpophalangeal joint; MTP,
metatarsophalangeal joint.Although this is a cross-sectional study except for
patient 5 and 6, comprehensive and detailed data from
patients at a wide range of ages who share the same
underlying molecular pathophysiology let us speculate on
the natural history of synovial inflammation in Blau syn-
drome. Comparing the siblings (patients 1 and 2), we
assume that mild GS tenosynovitis precedes clinically de-
tectable joint swelling and full-blown PD-positive teno-
synovitis; we also assume that tenosynovitis precedes
intra-articular synovitis. Given the minimal PD activity of
synovial inflammation in patient 10, who carries the same
NOD2 mutation as patient 2 but has never received treat-
ment, we also speculate that active synovial inflammation
can spontaneously ameliorate, at least in some patients
with Blau syndrome, at some point after their adolescence.
These hypotheses, however, need to be confirmed in a
large-scale observational study.
The marked improvement in PD scores in patients 5
and 6 after treatment with methotrexate plus infliximab
and relatively low total PD scores in patients recei-
ving treatment with methotrexate plus TNF antagonists
(patients 3, 4, 7, and 9) support the notion that a metho-
trexate plus TNF antagonist regimen is efficacious not
only for RA [40,41] and JIA [42] but also for arthritis in
patients with Blau syndrome [43]. On the other hand, the
effectiveness of methotrexate monotherapy was not obvi-
ous in our small group of patients. We do not exclude the
possible influence of genotypes on the severity of arthritis
in patient 3 (D382E) and 4 (R587C), both of which were
not included in the previous analysis of the association
between genotype and phenotype [6]. A future investiga-
tion on the association between NOD2 genotypes and
ultrasound-defined severity of arthritis in a larger number
of patients may identify the high-risk genotypes for severe
synovial inflammation.
The symmetrical involvement of synovial tissues and the
effectiveness of methotrexate plus infliximab in our pa-
tients with Blau syndrome support the argument that
autoinflammatory diseases such as Blau syndrome and
autoimmune diseases such as RA share some phenotypic
manifestations and cytokine pathways that maintain arth-
ritis even though the contribution of innate/acquired im-
munity to pathogenesis is quite different between these
two categories of disease [44]. However, our study also
confirms the painless nature of arthritis in Blau syndrome,
which contrasts with RA. Our patients exhibited surpri-
singly little tenderness or pain (Table 2) in the presence of
active inflammation in both the intra-articular- and teno-
synovium (Figures 1 and 2). In addition, the elevation of
acute inflammatory responses was infrequent and mild,
which is consistent with some of the previous reports
[1,14]. These data were reflected in the poor correlations
of total ultrasound scores with tender joint count, pa-
tients’/parents’ global VAS, ESR, and CRP (Table 3),
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inflammation in Blau syndrome. The reasons for this
absence of canonical features of inflammation in the pre-
sence of synovial inflammation, along with the predo-
minance of tenosynovitis, caused by NOD2 mutations are
intriguing research questions in understanding the mo-
lecular mechanisms of inflammation.
On the other hand, the swollen joint count tended to
correlate with total ultrasound scores (Table 3), sug-
gesting that the swollen joint count is the most reliable
conventional measure that can reflect the global severity
of synovial inflammation in patients with Blau syn-
drome. At a joint level, however, active synovial inflam-
mation was frequently detected by ultrasound in joints
without swelling (Table 4). These data indicate that cli-
nically detected joint swelling is not as sensitive as ultra-
sound findings to represent synovial inflammation.
Given the significant improvement of clinical parame-
ters after treatment in patient 5 (Table 2), these mea-
sures may reflect the therapeutic effect of potent therapy
on arthritis when disease activity is very high. However,
in order to prevent structural damage and late-onset
functional impairment, treating patients to a minimal
disease activity state, which can be only evaluated by
ultrasound, may be important. Since the impact of syn-
ovial inflammation on structural and functional deterio-
ration in Blau syndrome can be substantially different
from that in RA and JIA, longitudinal assessment of
arthritis in Blau syndrome using quantitative measures
for structural damage (for example, radiographic score)
is urgently needed to determine the threshold of accept-
able activity of synovial inflammation. In the future, cli-
nical studies to establish optimized treatment strategies
(for example, treatment agent, treatment target) for arth-
ritis in Blau syndrome, ultrasound may play a significant
role in decreasing the sample size needed by providing
better quantification and sensitivity to change.
One of the major limitations of our study is the very
small sample size. However, Blau syndrome is a much
more homogeneous condition as compared with RA or
JIA, especially when the genetic mutation of NOD2 is con-
firmed. Also given the quantitative capability and the ex-
cellent reproducibility of ultrasonographic assessment of
synovial inflammation in the recent reports [22,29,36,37],
the comprehensive data obtained in this study are likely to
represent the pathophysiology of arthritis in Blau syn-
drome and provide more reliable information than the
mostly descriptive one in the previous reports.
Another major limitation of our study is that ultrasono-
graphic synovial pathologies were graded subjectively due
to the lack of currently available standardized measures for
children. Although our data support the use of ultrasound
in monitoring the disease activity of Blau syndrome, our
data cannot be readily generalizable and need to beconfirmed in future studies when standardized methods are
established. Furthermore, performing the comprehensive
ultrasound assessment we employed in this study is not
feasible in daily practice. The essential synovial sites to be
scanned should be determined not only by the frequency of
involvement, but also by the impact on structural and
functional deterioration in Blau syndrome. Although we
assume that PD signal is more essential than GS syno-
vitis in monitoring disease activity, careful gray-scale assess-
ment is fundamentally important to distinguish between
the inflammatory angiogenesis in synovial hypertrophy
and the feeding vessels in unossified cartilage in children.
Conclusions
The detailed anatomical distribution and severity of syn-
ovial inflammation revealed by comprehensive ultrasound
assessment confirm the frequently involved joints, the pre-
dominance of tenosynovitis, and the dissociation between
pain and inflammation in the arthritis of Blau syndrome.
Our data also give an insight into the treatment response
of arthritis in Blau syndrome and demonstrate that muscu-
loskeletal ultrasound can be a potent tool in monitoring
the activity of synovial inflammation and in investigating
the pathophysiology of arthritis in this rare but arche-
typical autoinflammatory condition.
Additional files
Additional file 1: A longitudinal view of the dorsal aspect of the 3rd
proximal interphalangeal joint in the right hand. Severe synovial
hypertrophy accompanies severe power Doppler signals.
Additional file 2: A longitudinal view of the flexor tendon of the
3rd finger in the right hand. Moderate tenosynovial hypertrophy
accompanies moderate power Doppler signals. Transverse views of this
lesion showed more severe findings.
Additional file 3: An oblique view of the anterior-lateral aspect of
the suprapatellar recess in the right knee. Severe synovial
hypertrophy accompanies severe power Doppler signals.
Additional file 4: A longitudinal view of the tibialis anterior tendon
in the right ankle. Severe tenosynovial hypertrophy accompanies
moderate to severe power Doppler signals.
Additional file 5: A longitudinal view of the dorsal aspect of the 3rd
metatarsophalangeal joint in the right foot. Mild to moderate synovial
hypertrophy accompanies moderate to severe power Doppler signals.
Additional file 6: A longitudinal view of the flexor tendon of the 1st
toe in the right foot. Severe tenosynovial hypertrophy accompanies
moderate power Doppler signals.
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